Unlike malignancies such as NSCLC, where reporting guidelines and treatment cut-offs are established, currently there is no validated scoring algorithm for assessment of PD-L1 status in EC [3,4,8,9]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.